Literature DB >> 27767994

Cholinergic Basal Forebrain Lesion Decreases Neurotrophin Signaling without Affecting Tau Hyperphosphorylation in Genetically Susceptible Mice.

Marion T Turnbull, Elizabeth J Coulson.   

Abstract

Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disease that destroys memory and cognitive function. Aggregates of hyperphosphorylated tau protein are a prominent feature in the brain of patients with AD, and are a major contributor to neuronal toxicity and disease progression. However, the factors that initiate the toxic cascade that results in tau hyperphosphorylation in sporadic AD are unknown. Here we investigated whether degeneration of basal forebrain cholinergic neurons (BFCNs) and/or a resultant decrease in neurotrophin signaling cause aberrant tau hyperphosphorylation. Our results reveal that the loss of BFCNs in pre-symptomatic pR5 (P301L) tau transgenic mice results in a decrease in hippocampal brain-derived neurotrophic factor levels and reduced TrkB receptor activation. However, there was no exacerbation of the levels of phosphorylated tau or its aggregation in the hippocampus of susceptible mice. Furthermore the animals' performance in a hippocampal-dependent learning and memory task was unaltered, and no changes in hippocampal synaptic markers were observed. This suggests that tau pathology is likely to be regulated independently of BFCN degeneration and the corresponding decrease in hippocampal neurotrophin levels, although these features may still contribute to disease etiology.

Entities:  

Keywords:  Alzheimer’s disease; basal forebrain; brain-derived neurotrophic factor (BDNF); cholinergic neuron; hippocampus; lesion; neurotrophin; tau hyperphosphorylation

Mesh:

Substances:

Year:  2017        PMID: 27767994     DOI: 10.3233/JAD-160805

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  Cortico-hippocampal memory enhancing activity of hesperetin on scopolamine-induced amnesia in mice: role of antioxidant defense system, cholinergic neurotransmission and expression of BDNF.

Authors:  Ismail O Ishola; Abosi A Jacinta; Olufunmilayo O Adeyemi
Journal:  Metab Brain Dis       Date:  2019-04-04       Impact factor: 3.584

Review 2.  Bioavailability of Hesperidin and Its Aglycone Hesperetin-Compounds Found in Citrus Fruits as a Parameter Conditioning the Pro-Health Potential (Neuroprotective and Antidiabetic Activity)-Mini-Review.

Authors:  Kamil Wdowiak; Jarosław Walkowiak; Robert Pietrzak; Aleksandra Bazan-Woźniak; Judyta Cielecka-Piontek
Journal:  Nutrients       Date:  2022-06-26       Impact factor: 6.706

3.  Acute Down-regulation of BDNF Signaling Does Not Replicate Exacerbated Amyloid-β Levels and Cognitive Impairment Induced by Cholinergic Basal Forebrain Lesion.

Authors:  Marion T Turnbull; Zoran Boskovic; Elizabeth J Coulson
Journal:  Front Mol Neurosci       Date:  2018-02-22       Impact factor: 5.639

4.  Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease.

Authors:  Jacki M Rorabaugh; Termpanit Chalermpalanupap; Christian A Botz-Zapp; Vanessa M Fu; Natalie A Lembeck; Robert M Cohen; David Weinshenker
Journal:  Brain       Date:  2017-11-01       Impact factor: 15.255

Review 5.  The Cholinergic System Modulates Memory and Hippocampal Plasticity via Its Interactions with Non-Neuronal Cells.

Authors:  Sara V Maurer; Christina L Williams
Journal:  Front Immunol       Date:  2017-11-08       Impact factor: 7.561

Review 6.  Regulation of cholinergic basal forebrain development, connectivity, and function by neurotrophin receptors.

Authors:  Zoran Boskovic; Sonja Meier; Yunpeng Wang; Michael R Milne; Tessa Onraet; Angelo Tedoldi; Elizabeth J Coulson
Journal:  Health Psychol Behav Med       Date:  2019-02-04

Review 7.  Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation.

Authors:  Rashmi Gamage; Ingrid Wagnon; Ilaria Rossetti; Ryan Childs; Garry Niedermayer; Rose Chesworth; Erika Gyengesi
Journal:  Front Cell Neurosci       Date:  2020-10-15       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.